Bajpai J, Pradhan A, Verma AK, Kant S. Use of hydroxychloroquine and azithromycin combination to treat the COVID-19 infection. World J Exp Med 2022; 12(3): 44-52 [PMID: 35765514 DOI: 10.5493/wjem.v12.i3.44]
Corresponding Author of This Article
Surya Kant, FCCP, Professor, Department of Respiratory Medicine, King George Medical University, Lucknow 226003, Uttar Pradesh, India. skantpulmed@gmail.com
Research Domain of This Article
Infectious Diseases
Article-Type of This Article
Minireviews
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Jyoti Bajpai, Ajay Kumar Verma, Department of Respiratory Medicine, King George's Medical University, Lukcnow, Lucknow 226003, Uttar Pradesh, India
Akshyaya Pradhan, Department of Cardiology, King George's Medical University, Lukcnow, Lucknow 226003, Uttar Pradesh, India
Surya Kant, Department of Respiratory Medicine, King George Medical University, Lucknow 226003, Uttar Pradesh, India
Author contributions: Bajpai J and Verma AK conceptualized the article design; Bajpai J, Pradhan A, and Verma AK searched the literature; Bajpai J and Pradhan A drafted the manuscript; A critical revision was done by Kant S, Verma AK, Pradhan A, and Bajpai J.
Conflict-of-interest statement: The authors declare that they have no conflict of interest.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Surya Kant, FCCP, Professor, Department of Respiratory Medicine, King George Medical University, Lucknow 226003, Uttar Pradesh, India. skantpulmed@gmail.com
Received: November 21, 2021 Peer-review started: November 21, 2021 First decision: January 12, 2022 Revised: January 24, 2022 Accepted: April 21, 2022 Article in press: April 21, 2022 Published online: May 20, 2022
Core Tip
Core Tip: The coronavirus disease 2019 (COVID-19) pandemic has raged across the globe imposing a huge burden on the health systems. In absence of definitive treatment or vaccines, many drugs with antiviral properties were repurposed for use against COVID-19 infection. Based on the results of preliminary success in observational studies, Hydroxychloroquine (HCQS) and azithromycin were used extensively in the initial part of pandemic in he management of COVID-19 pandemic. Subsequently, reports of QT prolongation emerged with HCQS and its combination therapy with azithromycin. Later on HCQS was discontinued by major guidelines including World Health Organization. The review traces the emergence and downfall of the combination therapy in management of COVID-19.
